Hostname: page-component-6dbcb7884d-64ff6 Total loading time: 0 Render date: 2025-02-14T03:33:22.988Z Has data issue: false hasContentIssue false
  • English
  • Français

Role of α1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms

Published online by Cambridge University Press:  04 December 2013

Stephen M. Stahl
Get access Rights & Permissions [Opens in a new window]

Abstract

ISSUE:The low incidence of extrapyramidal side effects associated with the atypical antipsychotic iloperidone may be linked to its unique binding profile of high affinity antagonism of both α1 adrenergic receptors and serotonin 2A receptors.

Type
Brainstorms
Information
CNS Spectrums , Volume 18 , Issue 6 , December 2013 , pp. 285 - 288
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Stahl, SM. Stahl's Essential Psychopharmacology, 4th ed. Cambridge, UK: Cambridge University Press; 2013.Google Scholar
2.Mitzenberg, MJ, Yoon, JH. An index of relative central α-adrenergic receptor antagonism by antipsychotic medications. Exp Clin Psychopharmacol. 2011; 19: 31–39.CrossRefGoogle Scholar
3.Tarazi, F, Stahl, SM. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012; 13(13): 1911–1922.CrossRefGoogle ScholarPubMed
4.Weiden, PJ, Cutler, AJ, Polymeropoulos, MH, Wolfgang, CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol. 2008; 23(2 Suppl 1): S12–19.CrossRefGoogle Scholar
5.Cutler, AJ, Kalali, AH, Mattingly, GW, Kunovac, J, Meng, X. Long-term safety and tolerability of iloperidone: results from a 25 week, open-label extension trial. CNS Spectr. 2013; 18(1): 43–54.CrossRefGoogle ScholarPubMed
6.National Institutes of Mental Health. Psychoactive Drug Screening Program. 2012. Available from: http://pdsp.med.unc.edu/indexR.html.Google Scholar
7.Marek, GJ, Aghahanian, GK. 5HT2A receptor or alpha 1 adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur J Pharmacol. 1999; 367: 197–206.CrossRefGoogle ScholarPubMed
8.Marek, GJ, Aghajanian, GK. Alpha 1B-adrenoceptor-medicated excitation of piriform cortical interneurons. Eur J Pharmacol. 1996; 305: 95–100.CrossRefGoogle ScholarPubMed
9.Pudovkina, OL, Cremers, T, Westerink, B. Regulation of the release of serotonin in the dorsal raphe nucleus by alpha 1 and alpha 2 adrenoceptors. Synapse. 2003; 50: 77–82.CrossRefGoogle Scholar
10.Amargós-Bosch, M, Adell, A, Bortolozzi, A, Artigas, F. Stimulation of alpha 1 adrenoceptors in the rat medial prefrontal cortex increases the local in vivo 5-hydroxytryptamine release: reversal by antipsychotic drugs. J Neurochem. 2003; 87(4): 831–842.CrossRefGoogle ScholarPubMed
11.Mitrano, D, Schroeder, JP, Smith, Y, etal. α-1 adrenergic receptors are localized on presynaptic elements in the nucleus accumbens and regulate mesolimbic dopamine transmission. Neuropsychopharmacology. 2012; 37(9): 2161–2172.CrossRefGoogle ScholarPubMed
12.Coteccia, S. The α1-adrenergic receptors: diversity of signaling networks and regulation. J Recept Signal Transduct Res. 2010; 30: 410–419.Google Scholar
13.Pudovkina, OL, Westerink, B. Functional role of alpha 1 adrenoceptors in the locus coeruleus: a microdialysis study. Brain Res. 2005; 1061: 50–56.CrossRefGoogle ScholarPubMed
14.Drouin, C, Blanc, G, Trovero, F, Glowinski, J, Tassin, J-P. Cortical alpha 1 adrenergic regulation of acute and sensitized morphine locomotor effects. Neuroreport. 2001; 12: 3483–3486.CrossRefGoogle ScholarPubMed
15.Svensson, TH. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27: 1145–1158.CrossRefGoogle ScholarPubMed